{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:42:18Z","timestamp":1760121738879},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1093\/jac\/dkp092","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T16:05:06Z","timestamp":1238429106000},"page":"1097-1103","source":"Crossref","is-referenced-by-count":6,"title":["Is \u03b2-interferon a promising therapeutic option for the management of hepatitis C?"],"prefix":"10.1093","volume":"63","author":[{"given":"Seyed Mohammadmehdi","family":"Hosseini-Moghaddam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afkham","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,3,27]]},"reference":[{"key":"key\n\t\t\t\t20170511114154_DKP092C1","volume-title":"Medical Microbiology","author":"Baron","year":"1996"},{"key":"key\n\t\t\t\t20170511114154_DKP092C2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev"},{"key":"key\n\t\t\t\t20170511114154_DKP092C3","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1572-0241.1998.00285.x","article-title":"Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon","volume":"93","author":"Montalto","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/003655299750025426","article-title":"Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators","volume":"34","author":"Barbaro","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C5","first-page":"71","article-title":"Interferon-beta induction\/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C","volume":"25","author":"Kim","year":"2005","journal-title":"Int J Clin Pharmacol Res"},{"key":"key\n\t\t\t\t20170511114154_DKP092C6","first-page":"1686","article-title":"Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection","volume":"49","author":"Tan","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.hepres.2003.09.005","article-title":"Efficacy of early retreatment with interferon beta for relapse in patients with genotype Ib chronic hepatitis C","volume":"28","author":"Nomura","year":"2004","journal-title":"Hepatol Res"},{"key":"key\n\t\t\t\t20170511114154_DKP092C8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1572-0241.2003.07655.x","article-title":"Natural beta interferon as an initial treatment for the elderly with chronic hepatitis C","volume":"98","author":"Komorizono","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/jir.1997.17.27","article-title":"Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C","volume":"17","author":"Castro","year":"1997","journal-title":"J Interferon Cytokine Res"},{"key":"key\n\t\t\t\t20170511114154_DKP092C10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0197-2456(96)80004-3","article-title":"Preliminary results of beta-interferon treatment in the elderly","volume":"17","author":"Terranova","year":"1996","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t20170511114154_DKP092C11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1442-200X.1995.tb03370.x","article-title":"Relation between serum hepatitis C virus-RNA levels and efficacy of interferon-beta therapy","volume":"37","author":"Minohara","year":"1995","journal-title":"Acta Paediatr Jpn"},{"key":"key\n\t\t\t\t20170511114154_DKP092C12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/jhep.2000.9409","article-title":"Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor\u2014a prospective randomized study of hepatitis C virus-related liver cancer","volume":"32","author":"Ikeda","year":"2000","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cyto.2005.08.011","article-title":"A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines","volume":"33","author":"Murata","year":"2006","journal-title":"Cytokine"},{"key":"key\n\t\t\t\t20170511114154_DKP092C14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0016-5085(93)90727-T","article-title":"A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C","volume":"105","author":"Kakumu","year":"1993","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C15","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.3748\/wjg.v11.i29.4484","article-title":"Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C","volume":"11","author":"Pellicano","year":"2005","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C16","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s10620-007-0129-2","article-title":"Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial","volume":"53","author":"Han","year":"2008","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170511114154_DKP092C17","first-page":"3216","article-title":"Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group","volume":"46","author":"Bernardinello","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C18","first-page":"692","article-title":"Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C","volume":"6","author":"Fukutomi","year":"2000","journal-title":"Med Sci Monit"},{"key":"key\n\t\t\t\t20170511114154_DKP092C19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/hep.1840180606","article-title":"Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta","volume":"18","author":"Kobayashi","year":"1993","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.510250343","article-title":"Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy","volume":"25","author":"Kurosaki","year":"1997","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2893.2004.00514.x","article-title":"Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients","volume":"11","author":"Cheng","year":"2004","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20170511114154_DKP092C22","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1023\/A:1005655428563","article-title":"High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group","volume":"45","author":"Shiratori","year":"2000","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170511114154_DKP092C23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3748\/wjg.v10.i5.733","article-title":"Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C","volume":"10","author":"Mochizuki","year":"2004","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0168-8278(00)00044-1","article-title":"Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy","volume":"34","author":"Fukutomi","year":"2001","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/107999002753675820","article-title":"Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response","volume":"22","author":"Enomoto","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"key\n\t\t\t\t20170511114154_DKP092C26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1744-9987.2007.00488.x","article-title":"A case report of interferon beta monotherapy for high hepatitis C viral load in dialysis patients","volume":"11","author":"Nakajima","year":"2007","journal-title":"Ther Apher Dial"},{"key":"key\n\t\t\t\t20170511114154_DKP092C27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000045125","article-title":"Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon","volume":"80","author":"Uchihara","year":"1998","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20170511114154_DKP092C28","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1681\/ASN.V9122344","article-title":"Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications","volume":"9","author":"Rostaing","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C29","first-page":"382","article-title":"Pharmacokinetic study of human natural beta-interferon in patients with end-stage renal failure","volume":"56","author":"Nakayama","year":"2001","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00007890-199808270-00010","article-title":"Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years","volume":"66","author":"Hanafusa","year":"1998","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20170511114154_DKP092C31","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/0168-8278(90)90160-S","article-title":"Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group","volume":"11","author":"Davis","year":"1990","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2169\/internalmedicine.43.931","article-title":"Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy","volume":"43","author":"Konishi","year":"2004","journal-title":"Intern Med"},{"key":"key\n\t\t\t\t20170511114154_DKP092C33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2893.1999.00168.x","article-title":"Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C","volume":"6","author":"Kakizaki","year":"1999","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20170511114154_DKP092C34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/10799900050151102","article-title":"Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta","volume":"20","author":"Ikeda","year":"2000","journal-title":"J Interferon Cytokine Res"},{"key":"key\n\t\t\t\t20170511114154_DKP092C35","first-page":"775","article-title":"Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C","volume":"50","author":"Kaito","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C36","first-page":"217","article-title":"Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin","volume":"57","author":"Nakajima","year":"2003","journal-title":"Acta Med Okayama"},{"key":"key\n\t\t\t\t20170511114154_DKP092C37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1386-6346(00)00080-2","article-title":"Randomized controlled trial of twice-a-day administration of natural interferon beta for chronic hepatitis C","volume":"18","author":"Yoshioka","year":"2000","journal-title":"Hepatol Res"},{"key":"key\n\t\t\t\t20170511114154_DKP092C38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2302\/kjm.55.111","article-title":"Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C","volume":"55","author":"Saito","year":"2006","journal-title":"Keio J Med"},{"key":"key\n\t\t\t\t20170511114154_DKP092C39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0168-8278(00)80373-6","article-title":"Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta","volume":"33","author":"Shiratori","year":"2000","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/jir.1997.17.65","article-title":"Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C","volume":"17","author":"Castro","year":"1997","journal-title":"J Interferon Cytokine Res"},{"key":"key\n\t\t\t\t20170511114154_DKP092C41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1034\/j.1600-0676.2000.020006437.x","article-title":"A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C","volume":"20","author":"Habersetzer","year":"2000","journal-title":"Liver"},{"key":"key\n\t\t\t\t20170511114154_DKP092C42","first-page":"181","article-title":"Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial","volume":"30","author":"Calleri","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C43","first-page":"185","article-title":"Intramuscular beta interferon for chronic hepatitis C: is it worth trying?","volume":"30","author":"Fesce","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C44","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1023\/A:1026625928117","article-title":"Differences between interferon-alpha and beta treatment for patients with chronic hepatitis C virus infection","volume":"44","author":"Furusyo","year":"1999","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170511114154_DKP092C45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2893.1995.tb00014.x","article-title":"Clinical efficacy of intramuscular human interferon-beta vs. interferon-alpha 2b for the treatment of chronic hepatitis C","volume":"2","author":"Perez","year":"1995","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20170511114154_DKP092C46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.11150\/kansenshogakuzasshi1970.70.690","article-title":"Sequential interferon-alpha and beta treatment in patients with chronic hepatitis C","volume":"70","author":"Miyajima","year":"1996","journal-title":"Kansenshogaku Zasshi"},{"key":"key\n\t\t\t\t20170511114154_DKP092C47","first-page":"596","article-title":"Treatment of posttransfusion non-A, non-B acute and chronic hepatitis with human fibroblast beta-interferon: a preliminary report","volume":"84","author":"Ohnishi","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3748\/wjg.v10.i1.12","article-title":"Safety of interferon beta treatment for chronic HCV hepatitis","volume":"10","author":"Festi","year":"2004","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.1840170113","article-title":"Depression of drug-metabolizing activity in the human liver by interferon-beta","volume":"17","author":"Okuno","year":"1993","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C50","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/BF02088244","article-title":"Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study","volume":"41","author":"Villa","year":"1996","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170511114154_DKP092C51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s535-002-8131-9","article-title":"Possible mechanisms of elevation of serum transaminase levels during interferon-beta therapy in chronic hepatitis C patients","volume":"37","author":"Fujimori","year":"2002","journal-title":"J Gastroenterol"},{"key":"key\n\t\t\t\t20170511114154_DKP092C52","first-page":"59","article-title":"Rapid evolution of chronic viral hepatitis into hepatocellular carcinoma after beta-interferon treatment","volume":"41","author":"Malaguarnera","year":"1999","journal-title":"Panminerva Med"},{"key":"key\n\t\t\t\t20170511114154_DKP092C53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2169\/internalmedicine.39.146","article-title":"Type 1 diabetes mellitus caused by treatment with interferon-beta","volume":"39","author":"Kado","year":"2000","journal-title":"Intern Med"},{"key":"key\n\t\t\t\t20170511114154_DKP092C54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1507\/endocrj.52.377","article-title":"A case of ovulatory cycle-dependent symptoms in woman with previous interferon beta therapy","volume":"52","author":"Nakamura","year":"2005","journal-title":"Endocr J"},{"key":"key\n\t\t\t\t20170511114154_DKP092C55","first-page":"3681","article-title":"Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)-beta in patients with chronic hepatitis C","volume":"83","author":"Ohno","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170511114154_DKP092C56","first-page":"175","article-title":"Case report of a monoclonal gammopathy in a patient with chronic hepatitis: effects of beta-IFN treatment","volume":"38","author":"Gattoni","year":"1996","journal-title":"Panminerva Med"},{"key":"key\n\t\t\t\t20170511114154_DKP092C57","first-page":"1748","article-title":"Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment","volume":"45","author":"Toccaceli","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"key\n\t\t\t\t20170511114154_DKP092C58","first-page":"43","article-title":"A case of autoimmune hemolytic anemia induced by IFN-beta therapy for type-C chronic hepatitis","volume":"41","author":"Kazuta","year":"1995","journal-title":"Fukushima J Med Sci"},{"key":"key\n\t\t\t\t20170511114154_DKP092C59","first-page":"1418","article-title":"Mono-arthritis following intensified interferon beta therapy for chronic hepatitis C","volume":"49","author":"Murata","year":"2002","journal-title":"Hepatogastroenterology"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/63\/6\/1097\/16862098\/dkp092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T18:31:51Z","timestamp":1633285911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkp092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,27]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,3,27]]},"published-print":{"date-parts":[[2009,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkp092","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3,27]]}}}